Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 11, 2010, Pages 2847-2858

  Kelly, Jennifer L ^a   Novak, Anne J ^b   Fredericksen, Zachary S ^b   Liebow, Mark ^b   Ansell, Stephen M ^b   Dogan, Ahmet ^b   Wang, Alice H ^b   Witzig, Thomas E ^b   Call, Timothy G ^b   Kay, Neil E ^b   Habermann, Thomas M ^b   Slager, Susan L ^b   Cerhan, James R ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ADULT; AIF1 GENE; APAF1 GENE; APOPTOSIS; APOPTOSIS PATHWAY GENE; ARTICLE; BAG1 GENE; BAG3 GENE; BAG4 GENE; BAG5 GENE; BAK1 GENE; BCL2L10; BCL2L11 GENE; BCL2L12 GENE; BCL2L13 GENE; BCL2L14 GENE; BCL2L2 GENE; BCLAF1 GENE; BID GENE; BIK GENE; BIRC3 GENE; BNIP2 GENE; BNIP3 GENE; CANCER RISK; CASP1 GENE; CASP10 GENE; CASP2 GENE; CASP3 GENE; CASP4 GENE; CASP5 GENE; CASP6 GENE; CASP7 GENE; CASP8 GENE; CASP9 GENE; CONTROLLED STUDY; DFFB GENE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HRK GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CASPASE 9; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 78549272409     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0581     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120 Suppl 12:1-39. (Pubitemid 46732571)
3. Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009;144:716-25.
4. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008;111:3322-30.
5. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003;88:212-8. (Pubitemid 37101499)
6. Dyer MJ. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol 2003;77:315-20.
7. Lin P, Jetly R, Lennon PA, Abruzzo LV, Prajapati S, Medeiros LJ. Translocation (18;22) (q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature. Hum Pathol 2008;39:1664-72.
8. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56. (Pubitemid 37328916)
9. Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res;34:837-42.
10. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007;14:44-55. (Pubitemid 44911893)
11. Basecke J, Griesinger F, Trumper L, Brittinger G. Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol 2002;81:64-75. (Pubitemid 36067578)
12. Hui D, Satkunam N, Al Kaptan M, Reiman T, Lai R. Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma. Mod Pathol 2006;19:1192-202. (Pubitemid 44268189)
13. Schuler F, Dolken L, Hirt C, et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009;124:958-63.
14. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet 2004;115:112-5.
15. Shin MS, Kim HS, Kang CS, et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 2002;99:4094-9.
16. Yamanaka K, Clark R, Dowgiert R, et al. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006;12:376-82.
17. Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK. Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma 2004;45:49-54. (Pubitemid 38181392)
18. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
19. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;109:3479-88.
20. Zhang Y, Wang R, Holford TR, et al. Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes Control 2007;18:351-9.
21. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92:960-9.
22. Novak AJ, Slager SL, Fredericksen ZS, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009;69:4217-24.
23. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007;28:704-12.
24. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
25. Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009;30:275-81.
26. Wang SS, Purdue MP, Cerhan JR, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-κB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009;4:e5360.
27. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;110:4455-63.
28. Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-κB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008;17:3161-9.
29. Schuetz JM, MaCarthur AC, Leach S, et al. Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. BMC Med Genet 2009;10:117.
30. Skibola CF, Bracci PM, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet 2009;41:873-5.
31. Slager SL, Goldin LR, Strom SS, et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2010;19:1098-102.
32. Lan Q, Morton LM, Armstrong B, et al. Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies. Blood 2009;114:264-7.
33. Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009;18:1259-70.
34. Jaffe ES, Harris N, Stein H, Vardiman J. World Health Organization classification of tumours, pathology, and genetics: tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
35. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 2005;15:269-75.
36. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques 2002;Suppl:56-8, 60-1.
37. The International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-96.
38. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
39. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, Inc.; 2000.
40. Taylor J, Tibshirani R. A tail strength measure for assessing the overall univariate significance in a dataset. Biostatistics 2006;7:167-81.
41. Storey JD. A direct approach to false discovery rates. J R Stat Soc B 2002;64:479-98.
42. Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A. A comprehensive evaluation of SNP genotype imputation. Hum Genet 2009;125:163-71.
43. Kitada S, Pedersen IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002;21:3459-74. (Pubitemid 34587716)
44. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002;415:922-6.
45. Pinon JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2009;27 Suppl 1:S41-52.
46. Allan LA, Clarke PR. Apoptosis and autophagy: regulation of caspase-9 by phosphorylation. FEBS J 2009;276:6063-73.
47. Achiron A, Feldman A, Mandel M, Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007;1107:155-67. (Pubitemid 47528792)